Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Curtis

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Blood|June 25, 2026
Beijing, Baltimore, or both: a randomized drawDavid J Curtis
British Journal of Haematology|February 18, 2017
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?David J Curtis
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2004
Modifier screens in the mouse: time to move forward with reverse geneticsDavid J Curtis
Leukemia Research|November 12, 2023
PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?Andrej Terzic, David J Curtis
Blood|May 14, 2026
CHIP and inflammatory bowel disease: adding fuel to the fireDavid J Curtis, Jasmine Singh
Cell Cycle (Georgetown, Tex.)|June 4, 2010
The thymus under siege: Lmo2 induces precancerous stem cells in a mouse model of T-ALLMatthew P McCormack, David J Curtis
Current Opinion in Hematology|May 27, 2014
The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemiaCedric S Tremblay, David J Curtis
Blood|December 18, 2025
Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What's next?David J Curtis, Geoffrey R Hill
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2010
The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemiaDavid J Curtis, Matthew P McCormack
The New England Journal of Medicine|October 1, 2025
Cyclophosphamide and Cyclosporin for GVHD Prevention. ReplyDavid J Curtis, John Reynolds, Geoffrey R Hill
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Blood|June 25, 2026
Beijing, Baltimore, or both: a randomized drawDavid J Curtis
British Journal of Haematology|February 18, 2017
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?David J Curtis
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2004
Modifier screens in the mouse: time to move forward with reverse geneticsDavid J Curtis
Leukemia Research|November 12, 2023
PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?Andrej Terzic, David J Curtis
Blood|May 14, 2026
CHIP and inflammatory bowel disease: adding fuel to the fireDavid J Curtis, Jasmine Singh
Cell Cycle (Georgetown, Tex.)|June 4, 2010
The thymus under siege: Lmo2 induces precancerous stem cells in a mouse model of T-ALLMatthew P McCormack, David J Curtis
Current Opinion in Hematology|May 27, 2014
The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemiaCedric S Tremblay, David J Curtis
Blood|December 18, 2025
Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What's next?David J Curtis, Geoffrey R Hill
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2010
The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemiaDavid J Curtis, Matthew P McCormack
The New England Journal of Medicine|October 1, 2025
Cyclophosphamide and Cyclosporin for GVHD Prevention. ReplyDavid J Curtis, John Reynolds, Geoffrey R Hill
Pageof 10